|
|
300 Technology Square, Fifth Floor
Cambridge, MA 02139 USA
phone:(617) 551-4700
fax:(617) 551-4701
|
|
| Symbol |
Private |
| Founded |
2003 |
| Employees |
|
|
|
| www.radiuspharm.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug therapies for osteoporosis and women's health. |
|
| Management |
| C. Richard Lyttle, PhD, President & CEO; Nick Harvey, Senior Vice President, Chief Financial Officer; Louis O'Dea, MB, BCh, BAO, FRCP(C), Senior Vice President, Chief Medical Officer; Chris Miller, PhD, JD, Vice President of Chemistry, Patent Counsel; Gary Hattersley, PhD, Vice President of Biology |
| |
|
|
| |
|
| Keywords |
| women's health, women's, womenshealth, therapy, osteoporosis, women's health, bone mass, fracture |
|
|
|
| Description |
|
Radius specializes in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. |
|
| Products / Services |
The company's pipeline includes: PTHrP/BA058, a bone anabolic candidate for osteoporosis; SERM/RAD190, a novel tissue-selective estrogen receptor modulator for hot flashes; SARM/RAD140, a novel bone and muscle anabolic agent for sarcopenias, osteoporosis, and aging-associated frailty; and ER-Beta, a smalll-molecule agonist for endometriosis, RA, & IBD.
|
|
| Technology / Differentiation |
| While currently available drugs have proven efficacious in increasing bone mass and reducing the incidence of fractures, there remains a significant need for new drugs that can build bone to prevent fractures with a high degree of long-term safety and convenience. Radius is focused on developing new classes of drugs to address these needs. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members